91 related articles for article (PubMed ID: 10393527)
1. Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients.
Göhring UJ; Schöndorf T; Kiecker VR; Becker M; Kurbacher C; Scharl A
Tumour Biol; 1999; 20(4):173-83. PubMed ID: 10393527
[TBL] [Abstract][Full Text] [Related]
2. [Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer].
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Ueno Y; Yamashita H; Nomura K; Ichiguchi O
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2271-5. PubMed ID: 1656890
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
4. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
5. High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis.
Schöndorf T; Göhring UJ; Becker M; Hoopmann M; Schmidt T; Rützel S; Rein DT; Ulrich U; Fechteler R; Bersch A; Mallmann P; Valter MM
Pathobiology; 2004; 71(4):217-22. PubMed ID: 15263811
[TBL] [Abstract][Full Text] [Related]
6. Expression of ras Rb1 and p53 proteins in human breast cancer.
Spandidos DA; Karaiossifidi H; Malliri A; Linardopoulos S; Vassilaros S; Tsikkinis A; Field JK
Anticancer Res; 1992; 12(1):81-9. PubMed ID: 1567185
[TBL] [Abstract][Full Text] [Related]
7. Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers.
Sumiya H; Masai M; Akimoto S; Yatani R; Shimazaki J
Eur J Cancer; 1990; 26(7):786-9. PubMed ID: 1699574
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
[TBL] [Abstract][Full Text] [Related]
9. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
10. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients.
Lundy J; Grimson R; Mishriki Y; Chao S; Oravez S; Fromowitz F; Viola MV
J Clin Oncol; 1986 Sep; 4(9):1321-5. PubMed ID: 3528401
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
Saccani Jotti G; Fontanesi M; Bombardieri E; Gabrielli M; Veronesi P; Bianchi M; Becchi G; Bogni A; Tardini A
Int J Biol Markers; 1992; 7(1):35-42. PubMed ID: 1349907
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
13. Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status.
Querzoli P; Marchetti E; Bagni A; Marzola A; Fabris G; Nenci I
Breast Cancer Res Treat; 1988 Sep; 12(1):23-30. PubMed ID: 3058236
[TBL] [Abstract][Full Text] [Related]
14. Expression of Kirsten-ras p21 in gastric cancer correlates with tumor progression and is prognostic.
Motojima K; Furui J; Kohara N; Izawa K; Kanematsu T; Shiku H
Diagn Mol Pathol; 1994 Sep; 3(3):184-91. PubMed ID: 7981894
[TBL] [Abstract][Full Text] [Related]
15. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland.
Agnantis NJ; Constantinidou AE; Papaevagelou M; Apostolikas N
Anticancer Res; 1994; 14(5B):2135-40. PubMed ID: 7530930
[TBL] [Abstract][Full Text] [Related]
16. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G
Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185
[TBL] [Abstract][Full Text] [Related]
17. The H-ras oncogene product p21 and prognosis in human breast cancer.
Watson DM; Elton RA; Jack WJ; Dixon JM; Chetty U; Miller WR
Breast Cancer Res Treat; 1991; 17(3):161-9. PubMed ID: 2039838
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
19. Ras p21 in breast tissue: associations with pathology and cellular localisation.
Going JJ; Anderson TJ; Wyllie AH
Br J Cancer; 1992 Jan; 65(1):45-50. PubMed ID: 1733441
[TBL] [Abstract][Full Text] [Related]
20. [Quantitative immunohistochemical study of ras oncogene product P21 in laryngeal carcinomas and its clinical importance].
Liu ZS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):295-6, 315. PubMed ID: 8192934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
